RLMD实时信号 | 通过Getagraph.com最大化利润

购买 107721 min ago

@ $5.51

发出时间: 15 Feb 2024 @ 04:13

回报率: -33.39%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 2.99 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:33):

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders...

Stats
今日成交量	19 780.00
平均成交量	213 674
市值	110.74M
EPS	$0 ( 2024-03-19 )
下一个收益日期	( $-0.900 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.120
ATR14	$0.0260 (0.71%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-31	Traversa Sergio	Buy	27 460	Common Stock
2024-01-30	Traversa Sergio	Buy	40 999	Common Stock
2024-01-29	Traversa Sergio	Buy	31 541	Common Stock
2024-01-31	Shenouda Maged	Buy	6 875	Common Stock
2024-01-30	Shenouda Maged	Buy	15 000	Common Stock

INSIDER POWER
66.71
Last 97 transactions
Buy: 7 635 369 \| Sell: 1 906 109

音量相关性

長: 0.17 (neutral)

短: -0.46 (neutral)

Signal:(31.368) Neutral

Relmada Therapeutics Inc 相关性

10 最正相关
TCRT	0.953
WISA	0.929
TTCF	0.925
MDVL	0.919
KVSB	0.918
VSTA	0.915
VIRX	0.914
QTEK	0.914
FNCH	0.913
AVO	0.912

10 最负相关
BNIXU	-0.92
STAY	-0.904
SLGN	-0.904
CCRC	-0.903
WEN	-0.903
MGI	-0.903
IBEX	-0.9
IMMR	-0.899
ISIG	-0.898
MNKD	-0.88

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Relmada Therapeutics Inc 相关性 - 货币/商品

0.33
( neutral )

0.36
( neutral )

0.00
( neutral )

0.22
( neutral )

0.41
( neutral )

-0.24
( neutral )

Relmada Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-3.28

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-3.28

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-5.30

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-8.06

Financial Reports:

No articles found.

Relmada Therapeutics Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.